H.Lundbeck, a global pharmaceutical company specialized in psychiatric and neurological disorders, has announced that the company further focuses its preclinical research pipeline with the divestment of two research programmes
More From BioPortfolio on "Lundbeck divests two preclinical research programmes to MindImmune Therapeutics"